Geron (NASDAQ:GERN) Announces Earnings Results

Geron (NASDAQ:GERN) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02, Zacks reports. Geron had a negative return on equity of 22.94% and a negative net margin of 35.48%.The company had revenue of $51.84 million for the quarter, compared to the consensus estimate of $50.59 million.

Here are the key takeaways from Geron’s conference call:

• Rytelo Q1 net revenue was $61.8M (up 31% YoY, 8% QoQ), demand grew ~6% QoQ, footprint expanded to ~1,450 prescribing accounts, and management says it is on track for 2026 revenue guidance of $220–$240M.
• The phase III IMpactMF trial is fully enrolled with an interim overall?survival event trigger expected in H2 2026, and management says a positive interim could materially strengthen imetelstat’s disease?modifying profile and support broader MDS uptake.
• Geron is evaluating multiple go?to?market models for Europe (not pursuing a large internal build?out), is conducting HTA/pricing work, and expects to announce its European commercial plan by year?end.
• Gross?to?net deductions rose to 21% (from 13% a year ago) due to increased 340B utilization and GPO contracting and are expected to remain in the low?to?mid 20s for 2026, which pressures realized net revenue.
• Total operating expenses declined ~9% YoY to $50.4M in Q1 and management reiterated Opex guidance of $230–$240M; cash was ~$341M at quarter end after planned bonus, severance and CMC investments.

Geron Stock Down 1.0%

GERN stock traded down $0.02 during trading on Friday, reaching $1.45. 6,744,805 shares of the company traded hands, compared to its average volume of 16,523,078. The business has a 50 day simple moving average of $1.59 and a 200 day simple moving average of $1.43. Geron has a 12 month low of $1.04 and a 12 month high of $2.01. The company has a market capitalization of $926.10 million, a price-to-earnings ratio of -13.14 and a beta of 0.68. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66.

Wall Street Analyst Weigh In

GERN has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Monday, April 27th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $2.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after purchasing an additional 8,123 shares during the period. E Fund Management Co. Ltd. increased its holdings in shares of Geron by 12.0% in the second quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 9,849 shares during the period. Velan Capital Investment Management LP increased its holdings in shares of Geron by 14.3% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 10,000 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Geron by 3.4% in the third quarter. ADAR1 Capital Management LLC now owns 456,176 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 15,000 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Geron by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 316,622 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 18,491 shares during the period. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.